Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators

Folia Histochemica et Cytobiologica

Volumn 49, Issue 3, 2011, Pages 452-457

  Makarewicz, Roman ^a   Zyromska, Agnieszka ^a   Andrusewicz, Hanna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Benign prostate hyperplasia; Biomarkers; Prostate cancer

Indexed keywords

CYCLIN D1; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CELL ADHESION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84856790688     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0064     Document Type: Article

References (33)

1. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
2. He Y, Franco OE, Jiang M et al. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res. 2007;67:8188-8197.
3. Gryczyński M, Pietruszewska W. Wybrane aspekty apoptozy i proliferacji komorkowej raka krtani. Otolaryngol Pol. 2002; 1:151-160.
4. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. End Rel Cancer. 2006;13: 739-749.
5. Nahum AE, Movsas B, Horwitz EM et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391-401.
6. Pastore Y, Jedlickova K, Guan Y et al. Mutations of von Hippel- Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet. 2003;73:412-419.
7. Alqawi O, Wang HP, Espiritu M et al. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic Res. 2007;47:788-797.
8. Phillips RJ, Mestas J, Gharaee-Kermani M et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3'-kinase/PTEN/AKT/ /mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005; 280:22473-22481.
9. Syed S, Tolcher A. Innovative therapies for prostate cancer treatment. Rev Urol. 2003;5:S78-S84.
10. Knillova J, Kolar Z. The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. Proteins of the Bcl-2 family and protein p53. Biomed Papers. 2003;147:3-10.
11. Harrison GM, Davies G, Martin TA et al. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep. 2006;15:199-206.
12. Ekici S, Cerwinka WH, Duncan R et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer. 2004;112;121-129.
13. Iczkowski KA, Omara-Opyene AL, Shah GV. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res. 2006;26:2863-2872.
14. Gasinska A, Kolodziejski L, Niemiec J et al. Clinical significance of biological differences between cavitated and solid form of squamous cell lung cancer. Lung Cancer. 2005; 49:171-179.
15. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-140.
16. Boltze C, Mundschenk J, Unger N et al. Expression profile of the telomeric complex discriminates between benign and malignant Pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4280-4286.
17. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54:1951-1960.
18. Carnell DM, Smith RE, Daley FM et al. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys. 2006;65:91-99.
19. Du Z, Fujiyama C, Chen Y et al. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl). 2003;116:1936-1939.
20. Cowen D, Troncoso P, Khoo VS et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res. 2002;8:1148-1154.
21. Li R, Heydon K, Hammond ME et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004;10:4118-4124.
22. Aaltomaa S, Karja V, Lipponen P et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res. 2006;26:4873-4878.
23. Comstock CE, Revelo MP, Buncher CR et al. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007;96:970-979.
24. Drobnjak M, Osman I, Scher HI et al. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891-1895.
25. Bubendorf L, Sauter G, Moch H et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol. 1996;148:1557-1565.
26. Tolonen TT, Tommola S, Jokinen S et al. Bax and Bcl-2 are focally overexpressed in the normal epithelium of cancerous prostates. Scan J Urol Nephrol. 2007;41:85-90.
27. Kolar Z, Murray PG, Scott K et al. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol. 2000;53:8-15.
28. Karaburun Paker S, Kilicarslan B, Ciftcioglu AM et al. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer. Pathol Oncol Res. 2001;7:209-212.
29. Fonseca GN, Srougi M, Leite KR et al. The role of HER2/ /neu, Bcl2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J. 2004;122:124-127.
30. Amirghofran Z, Monabati A, Gholijani N. Apoptosis in prostate cancer: bax correlation with stage. Int J Urol. 2005;12:340-345.
31. Bergera Z, Zalabardo S, Garcia-Tapia A et al. p53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival. Actas Urol Esp. 2000;24:307-313.
32. Lou G, Gao Y, Ning XM et al. Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase- 2, and matrix metalloproteinase-9 in Krukenberg tumor. World J Gastroenterol. 2005;11:5032-5036.
33. Aaltomaa S, Lipponen P, Ala-Opas M et al. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol. 2001;39:138-144.